In addition, clinical, pre-clinical and in vitro studies have shown that IL13Rα2 is a potential target for killing of glioma cells and its targeting by Car-T cells is under clinical trial investigation (Thaci et al., 2014; Brown et al., 2016). Here, IL13RA2 is linked to glioma.